[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100475926":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":31,"responsibleParty":50,"collaborators":53,"id":57,"slug":11,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":11,"eligibilityCriteria":61,"healthyVolunteers":58,"sex":62,"minAge":63,"maxAge":11,"enrollmentInfo":64,"targetDuration":11,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":11,"overallStatus":34,"whyStopped":11,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Define MAsS cut-point at transplant evaluation to identify those with high risk for adverse outcomes","EXPERIMENTAL",null,[13],"Diagnostic Test: MAsS",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DIAGNOSTIC_TEST","MAsS","Add MAsS to standard of care MRI scan",[9],[21],{"name":22,"affiliation":23,"role":24},"Elizabet Carey, MD","Mayo Cinic","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":11,"email":30},"Latasha Bunkley","CONTACT","480.342.5756","bunkley.latasha@mayo.edu",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Mayo Clinic Arizona","RECRUITING","Phoenix","Arizona","85259","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-112.07404,33.44838,{"lat":44,"lon":43},[47],{"name":48,"role":28,"phone":49,"phoneExt":11,"email":11},"Elizabeth Carey, MD","480-342-1094",{"type":24,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"Elizabeth Carey","Professor of Medicine",[54],{"name":55,"class":56},"Amra Medical AB","INDUSTRY","100475926",false,"NCT05477277","Adverse Outcomes and Mortality in Liver Transplant","Inclusion Criteria:\n\n1. All patients with end-stage liver disease undergoing evaluation for liver transplantation\n2. Patient clinically indicated for MRI during transplant candidacy evaluation\n3. Adult\n\nExclusion Criteria:\n\n1\\. Contra indication to MRI","ALL","18 Years",{"count":65,"type":66},100,"ESTIMATED","INTERVENTIONAL",[69],"NA","Prospective natural history pilot study to explore the link between muscle composition using an MRI-based Muscle Assessment Score (MAsS) and adverse outcomes in liver transplant candidates.",[72,73,74,75],"End Stage Liver DIsease","Sarcopenia","Sarcopenic Obesity","Cirrhosis","2025-08-12",{"date":78,"type":79},"2025-08-15","ACTUAL",{"date":81,"type":79},"2022-11-02",{"date":83,"type":66},"2027-07-01",{"name":5,"class":6},1]